423 related articles for article (PubMed ID: 32307022)
21. Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy.
Ho KF; Marchant T; Moore C; Webster G; Rowbottom C; Penington H; Lee L; Yap B; Sykes A; Slevin N
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e375-82. PubMed ID: 22197229
[TBL] [Abstract][Full Text] [Related]
22. Tumour treating fields therapy for glioblastoma: current advances and future directions.
Rominiyi O; Vanderlinden A; Clenton SJ; Bridgewater C; Al-Tamimi Y; Collis SJ
Br J Cancer; 2021 Feb; 124(4):697-709. PubMed ID: 33144698
[TBL] [Abstract][Full Text] [Related]
23. Dosimetric influences of rotational setup errors on head and neck carcinoma intensity-modulated radiation therapy treatments.
Fu W; Yang Y; Yue NJ; Heron DE; Saiful Huq M
Med Dosim; 2013; 38(2):125-32. PubMed ID: 23266161
[TBL] [Abstract][Full Text] [Related]
24. The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma.
Riley MM; San P; Lok E; Swanson KD; Wong ET
J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058901
[TBL] [Abstract][Full Text] [Related]
25. Understanding the impact of pelvic organ motion on dose delivered to target volumes during IMRT for cervical cancer.
Eminowicz G; Rompokos V; Stacey C; Hall L; McCormack M
Radiother Oncol; 2017 Jan; 122(1):116-121. PubMed ID: 27863962
[TBL] [Abstract][Full Text] [Related]
26. Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience.
Kumar N; Gy S; Dracham CB; Dey T; Madan R; Khosla D; Oinum A; Kapoor R
CNS Oncol; 2020 Sep; 9(3):CNS60. PubMed ID: 32945180
[No Abstract] [Full Text] [Related]
27. Adaptive radiotherapy and the dosimetric impact of inter- and intrafractional motion on the planning target volume for prostate cancer patients.
Böckelmann F; Putz F; Kallis K; Lettmaier S; Fietkau R; Bert C
Strahlenther Onkol; 2020 Jul; 196(7):647-656. PubMed ID: 32157345
[TBL] [Abstract][Full Text] [Related]
28. The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns.
Glas M; Ballo MT; Bomzon Z; Urman N; Levi S; Lavy-Shahaf G; Jeyapalan S; Sio TT; DeRose PM; Misch M; Taillibert S; Ram Z; Hottinger AF; Easaw J; Kim CY; Mohan S; Stupp R
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1269-1278. PubMed ID: 34963556
[TBL] [Abstract][Full Text] [Related]
29. Real-time adaptive planning method for radiotherapy treatment delivery for prostate cancer patients, based on a library of plans accounting for possible anatomy configuration changes.
Antico M; Prinsen P; Cellini F; Fracassi A; Isola AA; Cobben D; Fontanarosa D
PLoS One; 2019; 14(2):e0213002. PubMed ID: 30818345
[TBL] [Abstract][Full Text] [Related]
30. Dosimetric comparison of doses to organs at risk using 3-D conformal radiotherapy versus intensity modulated radiotherapy in postoperative radiotherapy of periampullary cancers: implications for radiation dose escalation.
Bahl A; Kapoor R; Tomar P; Singh OA; Gupta R; Sharma SC
JOP; 2013 Jan; 14(1):39-43. PubMed ID: 23306333
[TBL] [Abstract][Full Text] [Related]
31. A Dosimetric Analysis of Preoperative Intensity-modulated and Image-guided Radiation Therapy with and without Simultaneous Integrated Boost for Locally Advanced Rectal Cancer.
Yang Y; Feng L; Wang Y; Ge R; Gong H; Xie C; Wang J; Chen J; Lan Y; Ma L
Technol Cancer Res Treat; 2015 Oct; 14(5):557-63. PubMed ID: 24988052
[TBL] [Abstract][Full Text] [Related]
32. Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Laprie A; Ken S; Filleron T; Lubrano V; Vieillevigne L; Tensaouti F; Catalaa I; Boetto S; Khalifa J; Attal J; Peyraga G; Gomez-Roca C; Uro-Coste E; Noel G; Truc G; Sunyach MP; Magné N; Charissoux M; Supiot S; Bernier V; Mounier M; Poublanc M; Fabre A; Delord JP; Cohen-Jonathan Moyal E
BMC Cancer; 2019 Feb; 19(1):167. PubMed ID: 30791889
[TBL] [Abstract][Full Text] [Related]
33. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
Kesari S; Ram Z;
CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
[TBL] [Abstract][Full Text] [Related]
34. Comparison of different treatment planning approaches for intensity-modulated proton therapy with simultaneous integrated boost for pancreatic cancer.
Stefanowicz S; Stützer K; Zschaeck S; Jakobi A; Troost EGC
Radiat Oncol; 2018 Nov; 13(1):228. PubMed ID: 30466468
[TBL] [Abstract][Full Text] [Related]
35. Treatment planning comparison of IMPT, VMAT and 4π radiotherapy for prostate cases.
Tran A; Zhang J; Woods K; Yu V; Nguyen D; Gustafson G; Rosen L; Sheng K
Radiat Oncol; 2017 Jan; 12(1):10. PubMed ID: 28077128
[TBL] [Abstract][Full Text] [Related]
36. Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy.
Pohling C; Nguyen H; Chang E; Schubert KE; Nie Y; Bashkirov V; Yamamoto V; Zeng Y; Stupp R; Schulte RW; Patel CB
Bioelectrochemistry; 2023 Feb; 149():108287. PubMed ID: 36306728
[TBL] [Abstract][Full Text] [Related]
37. Tumor-Treating Field Arrays Do Not Reduce Target Volume Coverage for Glioblastoma Radiation Therapy.
Stachelek GC; Grimm J; Moore J; Huang E; Spoleti N; Redmond KJ; Lim M; Bettegowda C; Kleinberg L
Adv Radiat Oncol; 2020; 5(1):62-69. PubMed ID: 32051891
[TBL] [Abstract][Full Text] [Related]
38. Dose calculation accuracy using cone-beam CT (CBCT) for pelvic adaptive radiotherapy.
Guan H; Dong H
Phys Med Biol; 2009 Oct; 54(20):6239-50. PubMed ID: 19794241
[TBL] [Abstract][Full Text] [Related]
39. Progress and prospect in tumor treating fields treatment of glioblastoma.
Liu S; Shi W; Zhao Q; Zheng Z; Liu Z; Meng L; Dong L; Jiang X
Biomed Pharmacother; 2021 Sep; 141():111810. PubMed ID: 34214730
[TBL] [Abstract][Full Text] [Related]
40. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
